View Post

Personalized gene-edited immune cell therapy for patients with solid cancers: New data establishes approach for verifying patient-specific cancer mutation targets

In Clinical Trials by Barbara Jacoby

Source: PACT Pharma From: PR Newswire – PACT’s gene-edited T cells were observed to kill tumor cells by targeting patient-specific tumor mutation targets in non-clinical testing – The company is launching clinical studies of personalized targeted immune cell therapy for patients with solid cancers PACT Pharma, a leader in the fields of cancer immunology and cell therapy in collaboration with …

View Post

Q&A: Phase I clinical trials

In Clinical Trials by Barbara Jacoby

By: Devon Carter From: mdanderson.org Phase I clinical trials are the foundation for how we develop new cancer drugs. Typically, they involve only several dozen patients and study a new medicine’s effect on a variety of cancer types. David S. Hong, M.D., sat down with us to explain more about Phase I clinical trials and answer some of patients’ most …

View Post

Celsion Announces IRB Approval to Begin a Clinical Study of ThermoDox® Plus High Intensity Focused Ultrasound in Breast Cancer Patients at University Medical Center Utrecht in the Netherlands

In Clinical Trials by Barbara Jacoby

Source: Celsion CORP From: globenewswire.com An Investigator-Sponsored Phase I Safety and Feasibility Study Estimated to Begin Enrollment in the Second Half of 2019 The Study Further Reinforces the Broad Potential of ThermoDox to Treat a Range of Solid Tumors with Multiple Localized Heating Sources Celsion Corporation (NASDAQ: CLSN), an oncology drug-development company, announces that the University Medical Center Utrecht in …

View Post

BioTheryX Announces FDA approval of IND Application to Initiate Phase I Clinical Trial in Relapsed or Refractory Acute Myeloid Leukemia

In Clinical Trials by Barbara Jacoby

Expects Enrollment of Phase I Trial to Begin in the Third Quarter of 2019 BioTheryX, Inc. (“BioTheryX”), a biotechnology company creating new classes of drugs based on multi-kinase inhibition and targeted protein degradation, today announced that the U.S. Food and Drug Administration (“FDA”) has cleared BioTheryX’s investigational new drug application (“IND”) for BTX-A51, an oral multi-kinase inhibitor, for the treatment …

View Post

Therapeutics Discovery division advances novel small-molecule to clinic

In Clinical Trials by Barbara Jacoby

By: Clayton R. Boldt, Ph.D. From: mdanderson.org The Therapeutics Discovery division at MD Anderson Cancer Center has advanced a new small-molecule inhibitor of cancer metabolism to Phase I clinical trials. This new drug candidate marks the fourth novel therapeutic brought from concept to clinical trial by Therapeutics Discovery, a drug-discovery engine built within the walls of MD Anderson to eliminate …

View Post

New Experimental Therapy CAR NKT-Cells Tested In Cancer Patients For The First Time

In Clinical Trials by Barbara Jacoby

  By: Victoria Forster From: forbes.com CAR T-cells are becoming somewhat of a household name, but a new phase I trial is, for the first time, using CAR ‘NKT’ cells, featuring genetic modification of a different immune cell, natural killer cells. Natural killer T-cells have long been known to be important in mediating the immune system’s response to cancer, targeting both tumor …

View Post

UC San Diego Health treats 1st cancer patient with stem-cell derived natural killer cells

In Clinical Trials by Barbara Jacoby

Source: University of California-SanDiego From: eurekalert.org After 10 years in remission, Derek Ruff’s cancer returned, this time as stage IV colon cancer. Despite aggressive rounds of chemotherapy, palliative radiotherapy and immunotherapy, his disease progressed. In February 2019, as part of a phase I clinical trial at Moores Cancer Center at UC San Diego Health, Ruff became the first patient in …

View Post

Northern Biologics Reports Initial Phase I Data for MSC-1 at AACR

In Clinical Trials by Barbara Jacoby

From: businesswire.com Northern Biologics Inc., a company focused on developing first-in-class immuno-oncology products, today announced the presentation of initial results from the Phase I trial of their lead antibody, MSC-1, at the American Association for Cancer Research meeting in Atlanta, Georgia. MSC-1 is a humanized antibody against a soluble cytokine called LIF (see “About LIF” below). LIF plays a multi-faceted …

View Post

Carevive Awarded National Cancer Institute SBIR Fast-Track to Advance Symptom Management Clinical Decision Support Technology

In In The News by Barbara Jacoby

Source: Carevive From: prnewswire.com NCI awards Carevive with the only Fast-Track Phase I/II contract supporting the development of an innovative symptom management and electronic patient-reported outcome solution Carevive, a health technology company that builds cancer care management and patient engagement solutions to improve patient quality of life and clinical outcomes, announced today that it has been awarded a Phase I …

View Post

Implantable cancer vaccine

In Clinical Trials by Barbara Jacoby

A small implant can recruit and reprogram a patient’s own immune cells “on site” to kill cancer cells The Wyss Institute’s implantable, biodegradable cancer vaccine leverages immunotherapeutic methods and could one day help overcome melanoma, other cancers, infectious diseases, auto-immune diseases, as well as vaccinate against specific peptides, proteins, or antigens. The implant is a biodegradable polymer scaffold containing growth …